Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 119, Issue 7, Pages 6266-6273Publisher
WILEY
DOI: 10.1002/jcb.26863
Keywords
asbestos; exosomes; mesothelioma; proteomics
Categories
Funding
- UVM Department of Pathology Graduate Student Fellowship
- UVMMC/LCCRO
- DOD IDeA Award [W81XWH-13-PRCRP-IA]
- NIH from INBRE Program of the National Institute of General Medical Sciences [P20GM103449]
- U.S. Department of Defense [W81XWH-13-PRCRP-IA]
- NIH [P20GM103449, RO1 ES021110]
Ask authors/readers for more resources
Asbestos-induced diseases like fibrosis and mesothelioma are very aggressive, without any treatment options. These diseases are diagnosed only at the terminal stages due to lack of early stage biomarkers. The recent discovery of exosomes as circulating biomarkers led us to look for exosomal biomarkers of asbestos exposure in mouse blood. In our model, mice were exposed to asbestos as a single bolus dose by oropharyngeal aspiration. Fifty-six days later blood was collected, exosomes were isolated from plasma and characterized and subjected to proteomic analysis using Tandem Mass Tag labeling. We identified many proteins, some of which were more abundant in asbestos exposed mouse serum exosomes, and three selected proteins were validated by immunoblotting. Our study is the first to show that serum exosomal proteomic signatures can reveal some important proteins relevant to asbestos exposure that have the potential to be validated as candidate biomarkers. We hope to extrapolate the positive findings of this study to humans in future studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available